An empirical model of drug pricing and competition: a dynamic perspective Online publication date: Mon, 30-Dec-2013
by Rodrigo Refoios Camejo; Clare McGrath; Frans F.H. Rutten
International Journal of Economics and Business Research (IJEBR), Vol. 6, No. 2, 2013
Abstract: In this study we test the impact of competition and other market attributes on the pricing of pharmaceuticals. Three decades worth of market and pricing data were collected and the market for lipid-lowering agents used as a case study. Panel data and cross sectional methods were applied to develop two distinct econometric models: one dynamic longitudinal model continuously following molecules' prices; and one static launch price model considering market conditions at time of launch. The results show a consistent element of price competition reflected both in the launch price of new drugs and in the price observed throughout the molecules' lifecycle. Prices vary greatly depending on market conditions such as the number of competitors, the degree of market concentration, and the existence of generic versions of the molecule. The results also show that a dual competition model is in place with market attributes affecting prices differently depending on the therapeutic proximity of available competitors.
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Economics and Business Research (IJEBR):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email subs@inderscience.com
Our Blog 
Follow us on Twitter 
Visit us on Facebook